Table 1 Age-adjusted mortality rates of haematological cancers in Spain (per 100,000 European standard population) by sex and 5-year calendar period
From: Changes in period and cohort effects on haematological cancer mortality in Spain, 1952-2006
1952–1956 | 1957–1961 | 1962–1966 | 1967–1971 | 1972–1976 | 1977–1981 | 1982–1986 | 1987–1991 | 1992–1996 | 1997–2001 | 2002–2006 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Haematological cancer | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate | No. of deaths | Rate |
Hodgkin’s disease | ||||||||||||||||||||||
Men | 659 | 1.13 | 894 | 1.45 | 1,091 | 1.65 | 1,214 | 1.73 | 1,201 | 1.63 | 1,052 | 1.32 | 982 | 1.14 | 951 | 1.03 | 794 | 0.80 | 698 | 0.63 | 647 | 0.52 |
Women | 406 | 0.61 | 510 | 0.72 | 624 | 0.82 | 642 | 0.80 | 633 | 0.75 | 625 | 0.66 | 614 | 0.60 | 583 | 0.51 | 592 | 0.46 | 538 | 0.39 | 496 | 0.31 |
Male-to-female ratio1 (95% CI) | 1.84 (1.62–2.09) | 2.01 (1.80–2.24) | 2.01 (1.82–2.22) | 2.17 (1.97–2.39) | 2.17 (1.97–2.40) | 1.98 (1.80–2.19) | 1.92 (1.73–2.12) | 2.03 (1.82–2.25) | 1.73 (1.55–1.93) | 1.65 (1.46–1.85) | 1.67 (1.48–1.89) | |||||||||||
Non-Hodgkin’s lymphoma | ||||||||||||||||||||||
Men | 360 | 0.65 | 554 | 0.93 | 875 | 1.36 | 1,098 | 1.55 | 1,540 | 2.07 | 1,982 | 2.47 | 2,736 | 3.19 | 3,992 | 4.30 | 5,046 | 5.00 | 5,957 | 5.29 | 6,272 | 4.97 |
Women | 232 | 0.36 | 295 | 0.42 | 555 | 0.74 | 660 | 0.81 | 972 | 1.12 | 1,369 | 1.43 | 2,022 | 1.85 | 3,226 | 2.70 | 4,394 | 3.25 | 5,457 | 3.58 | 5,652 | 3.21 |
Male-to-female ratio1 (95% CI) | 1.82 (1.54–2.16) | 2.20 (1.90–2.54) | 1.84 (1.65–2.05) | 1.91 (1.73–2.11) | 1.85 (1.71–2.01) | 1.72 (1.61–1.85) | 1.72 (1.62–1.82) | 1.59 (1.52–1.67) | 1.54 (1.47–1.60) | 1.48 (1.42–1.54) | 1.55 (1.49–1.61) | |||||||||||
Multiple myeloma | ||||||||||||||||||||||
Men | 215 | 0.37 | 290 | 0.46 | 679 | 1.01 | 1,132 | 1.52 | 1,731 | 2.06 | 2,351 | 2.51 | 2,949 | 2.87 | 3,660 | 3.13 | 3,881 | 2.90 | ||||
Women | 197 | 0.27 | 294 | 0.37 | 683 | 0.78 | 1,145 | 1.16 | 1,642 | 1.44 | 2,311 | 1.81 | 2,984 | 2.09 | 3,717 | 2.27 | 3,920 | 2.11 | ||||
Male-to-female ratio1 (95% CI) | 1.35 (1.11–1.64) | 1.22 (1.04–1.44) | 1.30 (1.16–1.44) | 1.30 (1.20–1.42) | 1.43 (1.33–1.53) | 1.39 (1.31–1.47) | 1.37 (1.30–1.45) | 1.38 (1.31–1.44) | 1.38 (1.31–1.44) | |||||||||||||
Leukaemia | ||||||||||||||||||||||
Men | 1,592 | 2.63 | 2,435 | 3.77 | 3,128 | 4.50 | 3,648 | 4.93 | 4,224 | 5.56 | 4,927 | 6.06 | 5,881 | 6.75 | 6,562 | 7.03 | 7,132 | 7.03 | 7,748 | 6.86 | 8,547 | 6.67 |
Women | 1,338 | 1.94 | 2,097 | 2.82 | 2,778 | 3.55 | 3,073 | 3.67 | 3,576 | 4.01 | 4,109 | 4.21 | 4,630 | 4.27 | 5,316 | 4.45 | 5,674 | 4.27 | 6,166 | 4.12 | 6,609 | 3.81 |
Male-to-female ratio1 (95% CI) | 1.36 (1.26–1.46) | 1.33 (1.26–1.42) | 1.27 (1.20–1.33) | 1.34 (1.28–1.41) | 1.39 (1.32–1.45) | 1.44 (1.38–1.50) | 1.58 (1.52–1.64) | 1.58 (1.52–1.64) | 1.65 (1.59–1.71) | 1.67 (1.61–1.73) | 1.75 (1.69–1.81) | |||||||||||